Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy

Wilma Barcellini, Bruno Fattizzo, MD, Luisa Quattrocchi, Juri Alessandro Giannotta, MD, Semra Aydin, MD PhD, Federica Barone, MD, Cecilia Carbone, MD, Eloise Beggiato, Paola Bianchi, BSc, PhD, Eros Di Bona, MD, Rosario Notaro, MD, Anna Paola Iori

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138721

Published: 2020

Journal Articles

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Antonio M. Risitano, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Rosario Notaro, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Jong-Wook Lee, MD, Mingjun Huang, PhD, Michael Geffner, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 3514.

https://doi.org/10.1182/blood-2019-124748

Published: 2019

Journal Articles

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

Pierre-Edouard Debureaux, MD, Fabiana Cacace, Bruno G.P. Silva, MD, Federica Barone, MD, Rodrigo T Calado, MD, Flore Sicre de Fontbrune, Juliette Soret-Dulphy, MD, Patrizia Ricci, Michela Sica, PhD, Rosario Notaro, MD, Phillip Scheinberg, MD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Antonio M. Risitano, MD PhD, Régis Peffault de Latour, MD PhD, Camilla Frieri, MD

Blood (2019) 134 (Supplement_1): 3517.

https://doi.org/10.1182/blood-2019-125917

Published: 2019

Journal Articles

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M. Risitano, MD PhD, Jong Wook Lee, MD PhD, Rosario Notaro, MD, Robert A. Brodsky, MD, Austin Kulasekararaj, MBBS MDMRCP FRCPath, Jaroslaw P. Maciejewski, MD PhD, Mingjun Huang, PhD, Michael Geffner, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 2226.

https://doi.org/10.1182/blood-2019-124837

Published: 2019

Journal Articles

Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFNγ-Producing T Cells

Lucia Gargiulo, PhD, Michela Sica, PhD, Caterina Nannelli, BSc, Lucio Luzzatto, MD, Rosario Notaro, MD

Blood (2017) 130 (Supplement 1): 1166.

https://doi.org/10.1182/blood.V130.Suppl_1.1166.1166

Published: 2017

Journal Articles

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

MIchela Sica, PhD, Tommaso Rondelli, Patrizia Ricci, PhD, Maria De Angioletti, PhD, Antonio M Risitano, MD PhD, Rosario Notaro, MD

Blood (2016) 128 (22): 401.

https://doi.org/10.1182/blood.V128.22.401.401

Published: 2016

Journal Articles

Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)

Lucia Gargiulo, PhD, Yoshitaka Zaimoku, MD, Barbara Scappini, MD, Hiroyuki Maruyama, MD, Rie Ohumi, Lucio Luzzatto, MD, Shinji Nakao, MD PhD, Rosario Notaro, MD

Blood (2015) 126 (23): 2409.

https://doi.org/10.1182/blood.V126.23.2409.2409

Published: 2015

Journal Articles

Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab

Michela Sica, PhD, Annamaria Pellecchia, PhD, Margherita Berardi, BS, Lucia Gargiulo, PhD, Tolulase A Olutogun, MD, Giovanni Caocci, MD, Giorgio La Nasa, MD, Maria De Angioletti, PhD, Lucio Luzzatto, MD FRCP, FRCPath, Rosario Notaro, MD

Blood (2014) 124 (21): 4397.

https://doi.org/10.1182/blood.V124.21.4397.4397

Published: 2014

Journal Articles

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Antonio M. Risitano, MD, PhD, Patrizia Ricci, Caterina Pascariello, Maddalena Raia, Christoph Q Schmidt, Yingxue Li, Edimara S Reis, Michela Sica, PhD, Rosario Notaro, MD, Luigi Del Vecchio, MD, Fabrizio Pane, Daniel Ricklin, John D Lambris

Blood (2012) 120 (21): 370.

https://doi.org/10.1182/blood.V120.21.370.370

Published: 2012

Journal Articles

Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI)

Lucia Gargiulo, PhD, Michela Sica, PhD, Maria Papaioannou, MD, PhD, Giulia Talini, PhD, Aristeidis Chaidos, MD, PhD, Barbara Richichi, PhD, Andrei V Nikolaev, PhD, Cristina Nativi, PhD, Mark Layton, MD, Josu de la Fuente, MRCP, MRCPCH, FRCPath, Irene Roberts, Lucio Luzzatto, MD, FRCP, FRCPath, Rosario Notaro, MD, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 647.

https://doi.org/10.1182/blood.V120.21.647.647

Published: 2012

Journal Articles

Genetic Polymorphism of the Complement Receptor-1 ( CR1 ) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tommaso Rondelli, BS, Antonio M. Risitano, MD, PhD, Régis Peffault de Latour, MD, Benedetta Peruzzi, PhD, Ricci Patrizia, BS, Wilma Barcellini, MD, Anna Paola Iori, Carla Boschetti, MD, Veronica Valle, MD, Veronique Frémeaux-Bacchi, PhD, Maria De Angioletti, PhD, Gerard Socie, Lucio Luzzatto, MD, FRCP, FRCPath, Rosario Notaro, MD

Blood (2012) 120 (21): 983.

https://doi.org/10.1182/blood.V120.21.983.983

Published: 2012

Journal Articles

Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms

Margherita Berardi, BS, Tommaso Rondelli, BS, Maria Chiara Susini, MD, Annamaria Pellecchia, BS, Elisabetta Antonioli, MD, Luca Boni, MD, Lucio Luzzatto, MD, FRCP, FRCPath, Alessandro M. Vannucchi, MD, Rosario Notaro, MD

Blood (2012) 120 (21): 5055.

https://doi.org/10.1182/blood.V120.21.5055.5055

Published: 2012

Journal Articles

Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH)

David J Araten, MD, Rosario Notaro, MD, Nancy A Kernan, MD, Farid Boulad, MD, Hugo Castro-Malaspina, MD, Trudy N Small, M.D, Andromachi Scaradavou, MD, Heather Magnan, MD, Susan E Prockop, MD, Sara Chaffee, MD, Jason Gonsky, MD, PhD, Raymond Thertulien, MD, PhD, Roberto Tarquini, MD, Lucio Luzzatto, MD

Blood (2010) 116 (21): 4239.

https://doi.org/10.1182/blood.V116.21.4239.4239

Published: 2010

NARROW

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Two Distinct but Functionally Related Autoreactive T Cell Populations in Paroxysmal Nocturnal Hemoglobinuria and Idiopathic Aplastic Anemia: Glycosylphosphatidylinositol-Specific and IFNγ-Producing T Cells

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)

Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI)

Genetic Polymorphism of the Complement Receptor-1 ( CR1 ) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms

Thrombolytic Therapy for Reversal of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only